Antares Pharma Inc
ATRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
$5.98
6.9% upside
Current Fair Value
6.9% upsideUndervalued by 6.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-42,822,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.27 |
| Beta | 1.15 |
| Outstanding Shares | 170,104,000 |
Return
| Return on Equity | 22.86% |
|---|---|
| Return on Assets | 15.71% |
| Return on Invested Capital | 9.57% |
Valuation & Multiples
| P/E Ratio | 20.55 |
|---|---|
| PEG | -12.75 |
| Price to Sales | 5.59 |
| Price to Book Ratio | 5.59 |
| Enterprise Value to Revenue | -0.23 |
| Enterprise Value to EBIT | -2.24 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | -0.45 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Antares Pharma Inc
CEO: Robert Apple Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Com...